Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma

Exclusion Criteria

• •Previously treated with an mTOR inhibitor
• •Known to be allergic to cyclophosphamide
• •Life expectancy of less than 3 months
• •No measurable lesions according to RECIST 1.1
• •Eastern cooperative oncology group (ECOG) Performance status \>2
• •Major surgery less than 4 weeks prior to start of treatment
• •Known human immunodeficiency virus (HIV) positivity
• •A decreased renal function with calculated glomerular filtration rate (GFR) \< 30ml/min
• •Systemic anti-cancer therapy within 28 days prior to the first dose of study drug , or radiotherapy to a target lesion within 21 days prior to the first dose of study drug
• •Pregnant or lactating women
• •Other invasive malignancies diagnosed within the last 5 years, except non-melanoma skin cancer and localised cured prostate and cervical cancer